Asset Details
Do you wish to reserve the book?
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Do you wish to request the book?
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015
Overview
In this randomized study, the addition of lixisenatide, a glucagon-like peptide 1–receptor agonist, to usual care in patients with type 2 diabetes and a recent cardiovascular event did not alter the rate of subsequent major cardiovascular or other serious adverse events.
Randomized trials involving patients with new or established type 2 diabetes have shown that improved glucose control reduces the risk of microvascular complications,
1
–
3
with modest cardiovascular benefits suggested by meta-analyses and extended follow-up of clinical trials.
4
–
7
However, various studies indicate that, despite being effective in lowering the glucose and glycated hemoglobin levels, some hypoglycemic medications may increase, rather than reduce, the risk of cardiovascular events.
8
–
10
These unexpected findings prompted the reexamination of the regulatory approval processes for new antidiabetic therapies, which had been based primarily on the surrogate measure of glucose lowering with limited clinical-outcomes data. Since . . .
Publisher
Massachusetts Medical Society
Subject
Acute Coronary Syndrome - complications
/ Acute Coronary Syndrome - drug therapy
/ Aged
/ Angina
/ Angina, Unstable - complications
/ Cardiovascular Diseases - epidemiology
/ Cardiovascular Diseases - prevention & control
/ Diabetes
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - mortality
/ Female
/ Glucagon
/ Glucagon-Like Peptide-1 Receptor - agonists
/ Glucose
/ Glycated Hemoglobin A - analysis
/ Humans
/ Hypoglycemic Agents - adverse effects
/ Hypoglycemic Agents - therapeutic use
/ Male
/ Myocardial Infarction - complications
/ Pancreas
